DT05 Rec'd PCT/PT0 0 8 FEB 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wesley Peter Blackaby, et al.

Int'l Appln.

No. : PCT/GB03/03376

Int'l Date

Filed: 04 August 2003 (04/08/2003)

Serial No.: (To be assigned) Case No.: T1569YP

Filed: February 13, 2005

For : PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS

FOR GABA RECEPTORS

......

Commissioner for Patents

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

DATE OF DEPOSIT

28 2005

DXPRESS MAIL NO. EL 78987757 U.S.

1 HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL.

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEJANDRIA, VIRGINIA 223/13-1460.

MAILED BY_

Serial No.: Case No.:

To be assigned T1569YP

DT05 Rec'd PCT/PT0

0 8 FEB 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

g. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: February 13, 2005

Su	bstitute for form 1449A/PTO			COMPLETE OF LINOWN			
	NFORMATION 1	DIS	CLOSURE	Application Number	COMPLETE F TO STORY T		
				Filing Date D	795-Reg'd 3-2005 0 8 FEB 2005		
5	STATEMENT BY APPLICANT			First Named Inventor	Wesley Peter Blackaby et al		
				Group Art Unit			
	(use as many sheets as necessary)			Examiner Name			
Sheet	1	of	2	Attorney Docket Number	T1569YP		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		US 4 810 705		Bourguignon et al	03/07/1989	
		US 6 255 305		Broughton et al	07/03/2001	
			1			
				·		
<u> </u>						

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document		
				(if known)		MM-DD-YYYY		
			WO 02 38568		Merck Sharp & Dohme	05/16/2002		
			WO 02 22605		Merck Sharp & Dohme	03/21/2002		
			EP 0 072 726		SANOFI SA	02/23/1983		

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					Falent and Tradentary Office; U.S DEPARTMENT OF COMMERCE		
	Substitute for form 1449B/PTC	2		COMPLETE IN KNOWN 521173			
	INFORMATIO		CLOSURE	Application Number [705 Rec'd PCT/PTO 0 8 :FEB 2005		
STATEMENT BY APPLICANT			DI ICANT	Filing Date	February 13, 2005		
			PLICANI	First Named Inventor	Wesley Peter Blackaby et al		
	,		,	Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Shee	2	of	2	Attorney Docket Number	T1569YP		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
		Wermuth, Camille Georges et al: "Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma - aminobutyric acid acting as selective GABA-A antagonists", JOURNAL OF MEDICINAL CHEMISTRY (1987) 30(2), 239-49.				
		Auricchio, Sergio et al: "New cleavage of the azirine ring by single electron transfer: the synthesis of 2H-imidazoles, pyridazines and pyrrolines", EUROPEAN JOURNAL OF ORGANIC CHEMISTY (2001), (6), 1183-1187.				
		Rival, Yveline et al: "5-HT3 Antagonists Derived from Aminopyridazine-type Muscarinic M1 Agonist", JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(3), 311-317.				
		South, Michael S. et al: "Synthesis and Reactions of Haloazodienes, A New and General Synthesis of Substituted Pyridazines", JOURNAL OF ORGANIC CHEMISTRY (1996), 61(25), 8921-8934.				
		Bly, Ruta K. et al: "Heterocyclic studies, XIII. The aldol condensation of 2,3-dihydro-5-methy 6-phenyl-4H-1, 2diazepin-4-one and rearrangement to a pyridazine", JOURNAL OF ORGANIC CHEMISTRY (1964), 29(8), 2128-35.				
		Chem. Abstract, XP002257945, 53:67737 Chemical Abstracts Service, Columbus, Ohio, US; Atkinson, C. M. et al: "Triazaphenanthrenes. III. Synthesis of some 9-aryl-2,3,10- triazapehanthrenes", JOURNAL OF THE CHEMICAL SOCIETY, (1959) 1-5				
		Chem. Absract, XP002257946, 126:18740 Chemical Abstracts Service, Columbus, Ohio, US; Samsonov, V. A. et al: "Preparation and reactions of pyrroline N-oxides obtained by reaction of isonitroso ketones with enamines", KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII (1996), (8), 1055-1061.				
		Harris, R.L.N. et al.: "The effect of C-2-carboxyphenyl Derivatives of Certain Heterocyclic Compounds on Root Geotropism in Cress Seedlings" PESTICIDE SCIENCE, vol. 11, 1980, pages 439-444.				
		Oliver, J.E. et al.: "Alkylatin and Rearrangement of Lithiated 3-Methyl-1,2-benziosoxazoles", JOURNAL OF ORGANIC CHEMISTRY, vol. 54, 1989, pages 4970-4973.				
	l	Breukelman, S.P.: "Preparation and some Reaction sof 4- and 5-Aryl-4,5-dihydropyrazin-3(2H-ones" J. CHEM. SOC. PERKIN TRANS., 1985, pages 1627-1635.				
		Jojma, T. et al.: "Pyridazine I. Novel Intramolecular Cycloaddition of 3-Chloro-6-(2-allylphenoxy)pyridazines" CHEMICAL&PHARMACEUTICAL BULLETIN, vol. 20, no. 10, 1972 pages 2191-2203.				
	;					
	<u></u>					

Examiner	Date	
Signature	Considered	
o.g.iatare	00	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.